A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood. Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s appro...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
Free AI-powered recaps of The BioCentury Show and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.